Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
  • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
  • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
  • A23L29/231—Pectin; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
  • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
  • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
  • A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
  • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

• the invention relates to a pharmaceutical or dietary preparation for reducing and / or blocking the adhesion of pathogenic substances and organisms to eukaryotic cells, in particular mammalian cells, which contains at least one antiadhesive carbohydrate with a uronic acid unit at one end, and the use of this preparation and the therein contained carbohydrates for the purposes mentioned.
• pathogenic organisms and cell-damaging substances to the surface of the mammalian cells is the first step and an essential prerequisite for infection or damage to the cell.
• the interaction between the pathogens and the cells comes about through a ligand-receptor relationship, which is therefore an important virulence or toxicity factor of the pathogens.
• Pathogens mean at least bacteria, viruses, fungi, unicellular and multicellular parasites, toxins and heavy metal cations. Glycostructures play an important role in this ligand-receptor relationship.
• One way to at least reduce or completely prevent this ligand-receptor relationship is to block the respective receptors on the cell surface or on the ligand.
• composition and structure of the naturally occurring carbohydrates and, for example, the carbohydrates of human milk are very complex.
• the same also applies to carbohydrates of vegetable origin or hydrolysis products of vegetable carbohydrates. It follows from this that the antiadhesive effect of carbohydrates for pathogens found in mammalian cells was mostly carried out with carbohydrate mixtures and not with purified individual structures.
• the object of the present invention is to show a way in which, with the aid of carbohydrates, the adhesion of pathogens is more effectively reduced or prevented by interaction with ligands and / or surface structures of eukaryotic cells and in particular mammalian cells.
• the invention thus relates, inter alia, to a pharmaceutical or dietary preparation which has at least one antiadhesive carbohydrate with a uronic acid unit at one of its ends.
• carbohydrates have at least two ends and can also have three or more ends if they are branched.
• straight-chain carbohydrates and also branched-chain carbohydrates can thus be used.
• At one of these ends is the named uronic acid unit, which has a terminal COOH group, which can be esterified.
• Preferred uronic acids or uronic acid units are the following free or esterified acids: galacturonic acid, glucuronic acid, guluronic acid, iduronic acid, mannuronic acid, riburonic acid and altruronic acid, of which galacturonic acid and glucuronic acid are particularly preferred.
• the preparation according to the invention contains at least one antiadhesive carbohydrate and thus a specific species with a uronic acid unit at one of its ends.
• the preparation according to the invention can also have several antiadhesive carbohydrates with a terminal uronic acid unit.
• the preparation according to the invention expediently contains a mixture of several such antiadhesive carbohydrates.
• antiadhesive carbohydrate is understood in the context of the present documentation to mean a carbohydrate which has a terminal uronic acid unit, regardless of whether this uronic acid unit has a double bond or not.
• antiadhesive carbohydrates denotes the sum of the carbohydrates with a uronic acid unit which have a double bond and those carbohydrates which have a uronic acid unit but which have no double bond.
• An essential idea of the invention is now that anti-adhesive carbohydrates are used that one Have minimum content of uronic acid units with a double bond.
• the antiadhesive carbohydrates can have a certain degree of polymerization, which is generally and therefore also abbreviated here as DP.
• antiadhesive carbohydrates with different DP's are usually present, and the antiadhesive carbohydrates with a certain degree of polymerization or DP can also have different compositions.
• the preparation according to the invention contains at least one specific antiadhesive carbohydrate species with a uronic acid unit at one of its ends. This carbohydrate species naturally has a certain DP.
• anti-adhesive carbohydrates with different DP may be present, with one or more anti-adhesive for each degree of polymerization
• Carbohydrate species can be present.
• The% gives the number of total uronic acid units with a double bond at one of the ends of the anti-adhesive carbohydrates with such a uronic acid unit, based on the sum of these uronic acid units with a double bond and any uronic acid units without such a double bond on one End of the anti-adhesive carbohydrate or anti-adhesive carbohydrates.
• a uronic acid unit at one end of an anti-adhesive carbohydrate is also referred to here as a terminal uronic acid unit.
• the antiadhesive carbohydrates used according to the invention which have such a uronic acid unit at one end can now have a non-reducing saccharide unit or also a reducing saccharide unit at the other end (in the case of a non-branched chain).
• 10 to 100% of the anti-adhesive carbohydrates having a terminal uronic acid unit have such a reducing saccharide unit at the other end (in the case of a straight chain) or at one of the other ends (in the case of a branched chain).
• 10 to 100% of the terminal uronic acid units are at a non-reducing end.
• even all of the terminal uronic acid units present can be present at the non-reducing end.
• the double bonds are between the C 4 and C 5 atoms of the terminal uronic acid units.
• the% is based on the number of double bonds, regardless of the DP of the antiadhesive carbohydrates and the saccharide units making up these antiadhesive carbohydrates.
• the detection of the double bond and thus of the terminal uronic acid units with such a double bond can be done spectroscopic at 235 nm using the molar extinction coefficient of 5500 l / mol cm, see TP Kravtchenko, I. Arnould, AGJ Voragen & W. Polnik Carbohydr. Polymer 1992, 19, 237-242.
• Carbohydrates with a reducing end are determined using iodometry according to the information in: Analytical Chemistry of Carbohydrates H. Scherz, G. Bonn, publisher Thieme Organic Chemistry Monograph Series, Stuttgart, New York, Thieme Verlag 1998, page 32.
• Carbohydrates with only non-reducing ends can be determined using conventional analysis methods, such as osmometry, mass spectrometry (eg MALDI-MS, ESI-MS), chromatography (eg GPC, HPAEC, HPLC) and capillary electrophoresis, or by a combination of these methods.
• the antiadhesive carbohydrates used according to the invention can also have a non-reducing end, for example by subsequently converting a reducing end into a non-reducing end. This can be achieved, for example, by oxidation, reduction or else by linking the reducing end to other molecules. These other molecules include, for example, proteins, lipids and industrial polymers, whereby (neo) glycoconjugates are obtained. This subsequent change in the reducing end has no influence on the anti-adhesive effect of the anti-adhesive carbohydrates used according to the invention. These anti-adhesive carbohydrates can thus also be immobilized on known carriers via a “formerly” reducing end, for example on a conventional carrier.
• an antiadhesive carbohydrate with a given degree of polymerization If, according to the invention, an antiadhesive carbohydrate with a given degree of polymerization is mentioned, then it can only be a single antiadhesive carbohydrate. However, there can also be several differently constructed anti-adhesive carbohydrates, the common features of which are the given degree of polymerization on the one hand and the terminal uronic acid unit on the other.
• the preparation according to the invention not only has one or more anti-adhesive carbohydrates with a given DP, but also several anti-adhesive carbohydrates of different degrees of polymerization.
• the applied Antiadhesive carbohydrates preferably have a degree of polymerization of DP2 to DP 40 and in particular DP 2 to DP 10 and a maximum of DP100. Mixtures of antiadhesive carbohydrates with different chain lengths are preferably used. In this case too, an antiadhesive carbohydrate with a certain chain length or a given degree of polymerization can be only a single carbohydrate species or several or any number of antiadhesive carbohydrate species.
• the antiadhesive carbohydrates with a terminal, in particular at the non-reducing end, double bonded uronic acid unit thus have an enhanced antiadhesive effect.
• These anti-adhesive carbohydrates are also referred to as unsaturated carbohydrates in the context of the present documents.
• the antiadhesive carbohydrates used according to the invention and thus also the unsaturated antiadhesive carbohydrates are obtainable, for example, by splitting acidic carbohydrates and preferably carbohydrates containing uronic acid by means of enzymes or chemical cleavage in such a way that the stated uronic acid unit contents are obtained with a double bond.
• Preferred raw materials are plants and / or parts of plants (such as carrots, citrus fruits, beets and apples, see C.
• the enzymatic cleavage is carried out in particular with the aid of lyases (such as pectin lyases or pectate lyases) or lyase-containing ones
• the process is carried out under neutral to alkaline conditions in order to obtain the desired double bond content.
• the degree of esterification of the carboxyl group and / or hydroxyl group can also be influenced by suitable selection of the further parameters, such as temperature, pH and buffer concentration.
• the antiadhesive carbohydrates used according to the invention and thus also the unsaturated antiadhesive carbohydrates can also be obtained with a cleavage carried out in the weakly acidic range.
• the anti-adhesive effect of the unsaturated anti-adhesive carbohydrates is also demonstrated by the presence of methyl esters of the carboxyl group as well as of acetylesters e.g. influenced at the C-2 and / or C-3 atom of the uronic acids. This applies in particular to the galacturonic acids of the pectins.
• the degree of methylation or acetylation is preferably 20 to 75% and in particular 20 to 50%.
• Carbohydrates in particular on the double bond of the uronic acid units located in particular at the non-reducing end. at the other saccharide units connected to this uronic acid unit having a double bond or no double bond of this type can be exclusively acidic carbohydrate units, exclusively neutral carbohydrate units and a mixture of acidic and neutral carbohydrate units. This is because the neutral carbohydrate units also influence the anti-adhesive effect of the unsaturated anti-adhesive carbohydrates. These are essentially rhamnose, arabinose, galactose, xylose, glucose, fucose and apiose, which in turn can be linked to feroyl residues and phenolic substances. This is especially true for pectins.
• the proportion of neutral carbohydrate units is preferably a maximum of 50% and in particular 0 to 30%.
• the preparation according to the invention can consist exclusively of an antiadhesive carbohydrate or a mixture of antiadhesive carbohydrates.
• the preparation is formulated, for example, as a tablet or as a food supplement.
• customary, pharmacologically acceptable carriers, diluents and / or auxiliaries can be present.
• These antiadhesive carbohydrates can also be incorporated into any food or pharmaceutical preparation which contain further ingredients.
• the other carbohydrates are a prebiotic carbohydrate mixture according to the teaching of WO 00/08948 with the international file number PCT / EP99 / 05878 and thus a prebiotic carbohydrate mixture of two different, essentially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and not absorbed to the colon, contains, wherein the carbohydrate component A is composed of at least one monosaccharide or at least one oligosaccharide (disaccharide up to hexasaccharide) or from a mixture of two or more of these saccharides , wherein the carbohydrate component B is composed of a polysaccharide (from heptasaccharide) or a mixture of two or more polysacc
• carbohydrate component A and carbohydrate component B make up carbohydrate component A and carbohydrate component B.
• components A and B are not assigned anti-adhesive carbohydrates.
• These carbohydrates, which make up the carbohydrate component A and the carbohydrate component B, are referred to below as prebiotic carbohydrates for reasons of simplicity of illustration, although only some of these carbohydrates have a real prebiotic effect.
• At least 80% by weight of the carbohydrates or saccharides, referred to as prebiotic, of the sum of carbohydrate components A and B thus have a prebiotic effect. At least 80% by weight preferably act the prebiotic carbohydrates belonging to the carbohydrate component A and also at least 80% by weight of the pebiotics belonging to the carbohydrate component B. In other words, preferably at least 80% by weight of the prebiotic carbohydrates or saccharides of carbohydrate components A and B must enter the colon undigested (and therefore not absorbable in the small intestine). In other words, these carbohydrates or saccharides
• Carbohydrate components A and B are not absorbed and digested in the gastrointestinal tract neither in the stomach nor in the small intestine, but reach the large intestine as such.
• Soluble carbohydrates of carbohydrate components A and B are to be understood as those which form a homogeneous solution in water in a concentration of at least 1 g / I at room temperature in the physical sense (e.g. according to Römpps Chemie Lexikon).
• the proportion of non-prebiotic carbohydrates or saccharides in carbohydrate components A and B is thus a maximum of 20% by weight.
• These carbohydrates or saccharides are those which are soluble but can be excreted undigested. These carbohydrates can have a physical effect, for example by increasing the stool volume or exercising water.
• the prebiotic carbohydrates / saccharides which make up the carbohydrate component A preferably have a different structure than the prebiotic carbohydrates / saccharides which make up the carbohydrate component B. Furthermore, at least 80% by weight of the prebiotic carbohydrates / saccharides of carbohydrate components A and B are preferred which promote lactic acid bacteria and / or are bifidogenic. The weight fraction of the carbohydrate component A is preferably greater than that Weight fraction of the carbohydrate component B. Die
• the prebiotic carbohydrates / saccharides of the carbohydrate components A and B in particular have no glucose units in ⁇ 1 -4 and / or in ⁇ 1 -6 bond.
• Carbohydrate component B are preferably composed of up to 100 monosaccharide units.
• At least 60% by weight and in particular 80 to 100% by weight of the prebiotic carbohydrates / saccharides of carbohydrate component A belong to the group of galactooligosaccharides and at least 60% by weight and in particular 80 to 100% by weight of the prebiotic carbohydrates / Saccharides of carbohydrate component B to the group of fructopolysaccharides.
• the weight ratio of the anti-adhesive carbohydrate (s) to the prebiotic carbohydrate mixture is preferably 1:99 to 99: 1 and in particular 1:10 to 10: 1 and furthermore in particular approximately 1: 1.
• the antiadhesive carbohydrates in addition to the antiadhesive carbohydrates and, in addition to the possibly present prebiotic carbohydrate mixture, other customary carbohydrates of any kind can also be present in the preparations according to the invention.
• These can be insoluble carbohydrates, soluble and digestible carbohydrates, common carbohydrates (e.g. starch, maltodextrins, lactose and sucrose) that are primarily used for nutritional purposes or a mixture of one or more of these carbohydrates act.
• the antiadhesive carbohydrates preferably make up 0.1 to 30 and in particular 1 to 10% by weight.
• the anti-adhesive oligosaccharides ensure that pathogenic substances do not bind to mammalian cells or that pathogens that have already been bound are detached.
• the addition of prebiotic oligosaccharides means that the disruption of the intestinal flora that often occurs in connection with pathogens is eliminated.
• pathogens in other places outside the gastointestinal tract such as the urogenital tract, the respiratory tract, the blood system and the skin, are combated by the systemic action of a balanced intestinal flora.
• the antiadhesive carbohydrates used according to the invention can be used not only to prevent or reduce infections or damage in the gastrointestinal tract but in all cells be used.
• the invention thus also relates to the use of the preparations according to the invention and the antiadhesive carbohydrates used therein to prevent or reduce the adhesion of pathogens to eukaryotic cells and in particular mammalian cells.
• These carbohydrates are preferably used for the treatment of infections of the gastrointestinal tract, the blood system, the respiratory tract, the urogenital tract, the nasopharynx and for the treatment of damage by toxins or heavy metal cations of the cells of the gastrointestinal tract, the blood system, the respiratory tract, the urogenital tract and the nasal tract. Pharynx used.
• the invention thus also relates to the use of the antiadhesive carbohydrates used Production of a dietetic or pharmaceutical preparation for the mentioned treatment purposes.
• the use is not limited to enterally administrable foods or pharmaceutical preparations. Rather, the antiadhesive carbohydrates used according to the invention can also be used as an active ingredient in pharmaceutical preparations which cannot be administered enterally.
• the preparations according to the invention can thus also be pharmaceutical preparations of this type which cannot be administered enterally.
• the supply amount of the antiadhesive carbohydrates used according to the invention and thus from the sum of carbohydrates which have a terminal uronic acid unit without a double bond and from carbohydrates which also have a terminal uronic acid unit but with a double bond (unsaturated carbohydrates), 10 to 100% of those present terminal uronic acid units have such a double bond is at least 8 mg / kg body weight and day, preferably 8 to 20 mg / kg body weight and day and in particular about 10 mg / kg and day.
• This information particularly preferably relates to the unsaturated antiadhesive carbohydrates alone.
• this range specification reveals all intermediate values and thus all values between the end values and also all narrower ranges covered by the ranges and claimed.
• the specification 8 to 20 mg / kg thus includes all values in between and in particular integer values, for example 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 mg / kg.
• the range specification 10 to 100% is therefore only a shortened specification for all conceivable intermediate values and in particular for the integer values 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 and 99%. This applies, for example, to the percentages for the proportion of uronic acid units with a double bond. All conceivable narrower areas are also included
• Examples 1 to 7 deal with the production of antiadhesive carbohydrates, with at least 10% of the uronic acid units present having a double bond.
• the products obtained are preparations that are made up exclusively of anti-adhesive carbohydrates.
• Examples 8 and 13 describe mixtures of antiadhesive carbohydrates and a prebiotic carbohydrate mixture in various
• 10 g of oligogalactoronides which were either prepared by enzymatic cleavage according to one of Examples 1, 3, 4 and / or 7, or were produced by chemical cleavage according to one of Examples 2, 5 and / or 6, are dried with 10 g of a prebiotic carbohydrate mixture of 9 parts galacto-oligosaccharides (e.g. Elixor from Borculo and Oligomate from Yakult) and 1 part high-molecular inulin (e.g. Raftiline HP from Orafti or Frutafit TEX or EXL from Fa. Sensus or Fibruline LC HAT from Cosucra) according to the proportions listed in the table below and mixed.
• a prebiotic carbohydrate mixture 9 parts galacto-oligosaccharides (e.g. Elixor from Borculo and Oligomate from Yakult) and 1 part high-molecular inulin (e.g. Raftiline HP from Orafti or Frutafit
• carbohydrate mixtures can also be used, which consist of the following components:
• ⁇ -galacto-oligosaccharides and inulin ⁇ -galacto-oligosaccharides and galactomannans, fructo-oligosaccharides and galactomannans, fructo-oligosaccharides and arabinogalactanes, ⁇ -galactooligosaccharides and arabinogalactanes and xylo-oligosaccharides as well as xylo-oligosaccharides.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Polymers & Plastics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Food Science & Technology (AREA)
• Nutrition Science (AREA)
• Organic Chemistry (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Mycology (AREA)
• Epidemiology (AREA)
• Pulmonology (AREA)
• Dispersion Chemistry (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Urology & Nephrology (AREA)
• Otolaryngology (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Toxicology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Virology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Adhesives Or Adhesive Processes (AREA)
• Materials For Medical Uses (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Steroid Compounds (AREA)
• Dental Preparations (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)

Priority Applications (20)

Applications Claiming Priority (2)

Related Child Applications (3)

Publications (2)

Family

ID=7631150

Family Applications (1)

Country Status (26)

Cited By (27)

Families Citing this family (21)

Family Cites Families (10)

• 2000
  • 2000-02-16 DE DE10006989A patent/DE10006989A1/de not_active Withdrawn
• 2001
  • 2001-02-16 EP EP10181824A patent/EP2298325A1/de not_active Withdrawn
  • 2001-02-16 AU AU2001246441A patent/AU2001246441B2/en not_active Ceased
  • 2001-02-16 CZ CZ20022702A patent/CZ20022702A3/cs unknown
  • 2001-02-16 ES ES01919291T patent/ES2370478T3/es not_active Expired - Lifetime
  • 2001-02-16 CN CN200710100849.6A patent/CN101057853B/zh not_active Expired - Fee Related
  • 2001-02-16 NZ NZ520642A patent/NZ520642A/en not_active IP Right Cessation
  • 2001-02-16 CN CN01805223A patent/CN1404395A/zh active Pending
  • 2001-02-16 DK DK01919291.3T patent/DK1267891T3/da active
  • 2001-02-16 HK HK03106357.1A patent/HK1053986A1/zh unknown
  • 2001-02-16 PT PT01919291T patent/PT1267891E/pt unknown
  • 2001-02-16 AT AT01919291T patent/ATE517628T1/de active
  • 2001-02-16 JP JP2001559474A patent/JP4965043B2/ja not_active Expired - Fee Related
  • 2001-02-16 US US10/182,739 patent/US20030022863A1/en not_active Abandoned
  • 2001-02-16 BR BRPI0108354-6A patent/BR0108354B1/pt not_active IP Right Cessation
  • 2001-02-16 PL PL363272A patent/PL204585B1/pl unknown
  • 2001-02-16 CA CA2400244A patent/CA2400244C/en not_active Expired - Fee Related
  • 2001-02-16 EP EP01919291A patent/EP1267891B1/de not_active Expired - Lifetime
  • 2001-02-16 MX MXPA02007970A patent/MXPA02007970A/es active IP Right Grant
  • 2001-02-16 WO PCT/EP2001/001753 patent/WO2001060378A2/de not_active Ceased
  • 2001-02-16 EP EP10183673A patent/EP2305270A1/de not_active Withdrawn
  • 2001-02-16 SK SK1168-2002A patent/SK288087B6/sk not_active IP Right Cessation
  • 2001-02-16 AU AU4644101A patent/AU4644101A/xx active Pending
  • 2001-02-16 RU RU2002124589/15A patent/RU2267324C2/ru not_active IP Right Cessation
  • 2001-02-16 HU HU0300409A patent/HUP0300409A3/hu not_active IP Right Cessation
  • 2001-02-16 CA CA2765218A patent/CA2765218A1/en not_active Abandoned
  • 2001-02-16 TR TR2002/02008T patent/TR200202008T2/xx unknown
• 2002
  • 2002-08-02 ZA ZA200206177A patent/ZA200206177B/en unknown
  • 2002-08-14 NO NO20023846A patent/NO331735B1/no not_active IP Right Cessation
  • 2002-08-15 IL IL151274A patent/IL151274A/en not_active IP Right Cessation
• 2005
  • 2005-12-22 US US11/313,674 patent/US7759324B2/en not_active Expired - Fee Related
• 2006
  • 2006-08-29 US US11/511,500 patent/US7919479B2/en not_active Expired - Fee Related
• 2011
  • 2011-03-02 US US13/038,741 patent/US20110152168A1/en not_active Abandoned
  • 2011-07-14 NO NO20111024A patent/NO20111024L/no not_active Application Discontinuation
  • 2011-10-27 CY CY20111101027T patent/CY1111968T1/el unknown

Also Published As

Similar Documents

Legal Events